FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized phase II study trial that has served as a screening trial to test the
increased efficacy of chemotherapy + cetuximab versus chemotherapy alone among patients with
untreated, advanced or metastatic colon cancer regardless of tumor status with respect to
EGFR.
Phase:
Phase 3
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborators:
Bristol-Myers Squibb Eli Lilly and Company ImClone LLC National Cancer Institute (NCI)